Insights

Global expansion potential ANEUVO has CE Mark approved ExaStim system in Europe and US investigational use, indicating regulatory progress and international opportunities for partnerships, clinical trials, and potential distribution deals beyond Europe as the product advances.

Strategic partnerships With a Breakthrough Device designation and ongoing US study launches, there is strong potential to collaborate with contract research organizations, medical distributors, and hospital networks to accelerate trials, scale adoption, and secure reimbursement pathways.

Clinical validation Recent awards and demonstrated implementations at RehaCare ISCoS, plus a US study, provide talking points for customer prospects about efficacy in spinal cord injury and neuromodulation, aiding evidence-based sales conversations.

Market positioning Position ANEUVO as a non-invasive neuromodulation leader for SCI, targeting clinics and specialty centers seeking alternatives to surgical or pharmaceutical approaches, while leveraging prestige from international innovation awards.

Funding momentum Recent $22M Series C funding signals investor confidence and financial runway to scale manufacturing, regulatory activities, and sales efforts, enabling faster market entry and broader coverage.

ANEUVO Tech Stack

ANEUVO uses 8 technology products and services including Atlassian, Amazon Web Services, Google Fonts API, and more. Explore ANEUVO's tech stack below.

  • Atlassian
    Application Development & Management
  • Amazon Web Services
    Cloud Hosting
  • Google Fonts API
    Font Scripts
  • Selenium
    Frameworks And Libraries
  • JSON-LD
    Javascript Frameworks
  • Yoast SEO Premium
    Search Engines
  • Bitbucket
    Source Code Management
  • Minitab
    Visualisation Software

ANEUVO's Email Address Formats

ANEUVO uses at least 2 format(s):
ANEUVO Email FormatsExamplePercentage
First@aneuvo.comJohn@aneuvo.com
50%
FirstL@aneuvo.comJohnD@aneuvo.com
25%
FLast@aneuvo.comJDoe@aneuvo.com
25%
First@nichebio.comJohn@nichebio.com
100%

Frequently Asked Questions

What is ANEUVO's official website and social media links?

Minus sign iconPlus sign icon
ANEUVO's official website is aneuvo.com and has social profiles on LinkedInCrunchbase.

How much revenue does ANEUVO generate?

Minus sign iconPlus sign icon
As of July 2026, ANEUVO's annual revenue is estimated to be $1M - $10M.

What is ANEUVO's NAICS code?

Minus sign iconPlus sign icon
ANEUVO's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does ANEUVO have currently?

Minus sign iconPlus sign icon
As of July 2026, ANEUVO has approximately 26 employees across 3 continents, including North AmericaAsiaSouth America. Key team members include Vice President Of Operations And Sales, Imaging: L. R.Advisory Board Member: B. M.. Explore ANEUVO's employee directory with LeadIQ.

What industry does ANEUVO belong to?

Minus sign iconPlus sign icon
ANEUVO operates in the Medical Equipment Manufacturing industry.

What technology does ANEUVO use?

Minus sign iconPlus sign icon
ANEUVO's tech stack includes AtlassianAmazon Web ServicesGoogle Fonts APISeleniumJSON-LDYoast SEO PremiumBitbucketMinitab.

What is ANEUVO's email format?

Minus sign iconPlus sign icon
ANEUVO's email format typically follows the pattern of First@aneuvo.com. Find more ANEUVO email formats with LeadIQ.
ANEUVO logo

ANEUVO

Medical Equipment ManufacturingCalifornia, United States11-50 Employees

ANEUVO is a medical equipment manufacturing company based in Los Angeles, California, focused on developing platform-based therapies for disabling diseases and conditions that have not responded to traditional pharmaceutical approaches. Its ExaStim® Stimulation System is a non-invasive neuromodulation device that has received regulatory designations indicating potential use in treating spinal cord injury, though its clearance is limited to Europe and it remains investigational in the United States. The company operates within the medical technology sector, aiming to address unmet needs through neuromodulation therapies that may complement or offer alternatives to existing treatments for SCI patients.

Targeting patients with spinal cord injury and related conditions, ANEUVO emphasizes non-invasive approaches designed to stimulate neural activity and support rehabilitation. The organization positions itself as a development platform in medical technology, pursuing therapies that have progressed through regulatory pathways and are presented at industry events, with a focus on advancing non-invasive neuromodulation for SCI. The company is described as having a presence in the Los Angeles area and operates as a smaller enterprise within the broader medical device landscape.

Section iconCompany Overview

Website
aneuvo.com
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Employees
11-50

Section iconFunding & Financials

  • $1M - $10M

    ANEUVO's revenue is estimated to be in the range of $1M - $10M

Section iconFunding & Financials

  • $1M - $10M

    ANEUVO's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.